drugset / Trial / NCT07030127
A Study of LY3985863 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Timeline
- Start
- 2025-08-11
- Primary completion
- 2026-02-24
- Completion
- 2026-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimagrumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.